finasteride has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamowicz, J; Drewa, T; Juszczak, K | 1 |
| Cadegiani, FA; Comeche, B; Gioia, F; Goren, A; Herrera, S; Kovacevic, M; McCoy, J; Ramos, PM; Ron, R; Serrano-Villar, S; Shapiro, J; Sinclair, R; Tosti, A; Vaño-Galván, S; Wambier, CG | 1 |
2 other study(ies) available for finasteride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Topics: 5-alpha Reductase Inhibitors; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Finasteride; Humans; Lung; Male; Pandemics; Pneumonia, Viral; Prognosis; Prostatic Hyperplasia; Respiratory Mucosa; SARS-CoV-2; Sex Factors | 2020 |
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; COVID-19; Dutasteride; Finasteride; Humans; Intensive Care Units; Male; Middle Aged; Observational Studies as Topic; Patient Admission; Prospective Studies; SARS-CoV-2; Spironolactone | 2021 |